Ganciclovir pharmacokinetics during renal impairment.
Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.
Lake
K D
KD
Division of Cardiothoracic Transplantation and Research, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minnesota.
Fletcher
C V
CV
Love
K R
KR
Brown
D C
DC
Joyce
L D
LD
Pritzker
M R
MR
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000328:Adult; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D005260:Female; D015774:Ganciclovir; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D006435:Renal Dialysis
D015774:Ganciclovir; D000212:Acyclovir